Effect of Renal Impairment on Enpatoran Pharmacokinetics
This early-stage study, called a Human Pharmacology (Phase I) trial, is investigating a new medicine called Enpatoran. Researchers want to understand how this medicine is processed by the body, especially in people who have kidney problems. They will compare how Enpatoran works in healthy volunteers to how it works in people with different levels of kidney impairment. This is important because kidney function can affect how medicines are cleared from the body. Enpatoran is being developed to treat autoimmune diseases like lupus (both systemic and skin forms), as well as dermatomyositis and polymyositis. Understanding its behaviour in people with kidney issues helps ensure it can be given safely and effectively in the future.
At a glance
What is this study about?
This research is looking into a new medicine called Enpatoran. This medicine is currently being developed to help people with certain autoimmune diseases. Autoimmune diseases happen when your body's immune system mistakenly attacks healthy parts of your body. Examples include lupus (systemic lupus erythematosus and cutaneous lupus erythematosus), dermatomyositis, and polymyositis.
The main goal of this study is to understand how Enpatoran works in the body, particularly how it's handled by people with kidney problems. When you take a medicine, your body processes it, and your kidneys often play a big role in getting rid of the medicine from your system. If your kidneys aren't working as well as they should, it might affect how much medicine stays in your body and for how long. This study will compare how healthy volunteers process Enpatoran to how people with different levels of kidney impairment process it.
This is a very early-stage study, often called a Phase I trial. It's crucial for gathering basic information about a new medicine, like how much to give and how often, especially for people with specific health conditions like kidney issues. The information gained from this study will help ensure that if Enpatoran becomes available in the future, it can be used safely and effectively for all patients who might need it, even those with kidney problems.
Key takeaways
- This study investigates a new medicine called Enpatoran.
- It aims to understand how Enpatoran is handled by the body, especially in people with kidney problems.
- The medicine is being developed for autoimmune conditions like lupus and dermatomyositis.
- It's an early-stage study (Phase I) to gather important safety and dosing information.
- Both healthy volunteers and people with kidney impairment can take part.
- The study helps ensure future safe use of the medicine.
Who may be eligible?
This study is open to both men and women who are 18 years old or older. You could be a healthy volunteer, meaning you don't have existing health conditions, or you could be someone who has kidney problems.
People with kidney impairment will be carefully checked to see the level of their kidney function. This helps the researchers understand how different levels of kidney health affect the medicine.
More detailed checks will happen during the screening process to make sure it's safe for you to take part and that you fit the specific requirements for the study. For instance, if you have certain other serious health conditions or are taking particular medications, you might not be able to join. These specific details would be discussed with you by the study team.
- Are you 18 years old or older?
- Are you a man or a woman?
- Are you generally healthy, OR do you have some level of kidney impairment?
- Are you willing to undergo detailed health checks to see if you fit the study's specific needs?
- Are you able to commit to the study's visits and procedures?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
The detailed information about what taking part involves is not provided in this summary. However, in a typical early-stage study like this, participants usually visit the study clinic multiple times. These visits might include taking the study medicine (Enpatoran), having blood and urine samples taken to check how the medicine is moving through your body, and undergoing regular health checks like blood pressure and heart rate measurements. You would be carefully monitored by doctors and nurses. The total duration of participation and the number of visits would be clearly explained to you by the study team before you decide to join.
Potential risks and benefits
Locations (1)
- —Germany
Common questions
What is Enpatoran?
Enpatoran is a new medicine being studied to treat autoimmune diseases like lupus.
What does 'pharmacokinetics' mean?
It's a scientific term that describes how a medicine moves through your body – how it's absorbed, distributed, processed, and eventually leaves your body.
Why is this study looking at people with kidney problems?
Many medicines are processed by the kidneys, so it's important to understand how Enpatoran works in people with kidney impairment to ensure it can be used safely and effectively.
What is a 'Phase I' study?
This is an early stage of human testing for a new medicine, focusing on its safety and how it works in the body, rather than how well it treats a disease yet.
Will I get the medicine for my condition if I have, say, lupus?
This study isn't designed to treat your condition but to understand how the medicine behaves in your body. It is an early-stage study focusing on safety and how the medicine works, not yet on treating your disease.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.